T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor SignalingSarah E. Josefsson, June H. Myklebust, Kanutte Huse et al.|Clinical Cancer Research|2017Cited by 95
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Eva Kimby, Stéphanie Rondeau et al.|Blood|2019Cited by 61
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Giovanni Martinelli et al.|Blood|2014Cited by 18
Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Stéphanie Rondeau et al.|Blood|2016Cited by 9
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Emanuele Zucca, Sämi Schär et al.|Blood Advances|2025Cited by 4